Cassava Sciences Enhances Leadership with New Board Appointment
Cassava Sciences, Inc. (NASDAQ: SAVA), a biotechnology company devoted to creating innovative treatments for central nervous system (CNS) disorders, announced recently that Ms. Dawn C. Bir has been appointed to its Board of Directors.
Ms. Dawn C. Bir: A Proven Biopharmaceutical Leader
Dawn Bir brings extensive experience to Cassava, having previously helped guide several biopharmaceutical companies through significant growth and transition phases. Her background includes key executive roles at notable organizations like Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics, demonstrating a strong ability to drive both clinical and commercial success.
Creating Shareholder Value
Claude Nicaise, MD, Chairman of the Board at Cassava, expressed enthusiasm about Ms. Bir's addition to the leadership team during a transformative time for the company. He stated, "Her commitment to enhancing shareholder value will be a valuable asset, and we eagerly anticipate the positive impact of her contributions.”
Preparing for Clinical Advancements
As Cassava readies itself for the initiation of its first clinical study of simufilam targeting TSC-related epilepsy, Rick Barry, the company's President and CEO, emphasized the need for strategic capabilities within the Board. He noted Ms. Bir's proven track record in establishing impactful relationships within the industry would be crucial as they advance their programs.
A Call to Action in CNS Research
Ms. Bir echoed this sentiment, highlighting the urgent need for new therapeutic options for TSC-related epilepsy. She expressed her excitement about working closely with Cassava’s committed management team to navigate the company’s business and clinical strategies, aiming to deliver significant advancements in treatment options for patients and their families.
About Cassava Sciences, Inc.
Cassava Sciences (NASDAQ: SAVA) is focused on innovative treatment solutions like simufilam for CNS disorders, including TSC-related epilepsy. Simufilam is a proprietary oral small molecule that aims to modulate the activity of the filamin A protein, which plays a vital role in neuronal development. The company's base of operations is located in Austin, Texas.
Contact Information
For further inquiries, interested parties can reach out to:
Investors:
Sandya von der Weid
Email: svonderweid@lifesciadvisors.com
Company:
Eric Schoen, Chief Financial Officer
(512) 501-2450
Email: ESchoen@CassavaSciences.com
Frequently Asked Questions
What is the main focus of Cassava Sciences?
Cassava Sciences is dedicated to developing novel treatments for central nervous system disorders, including epilepsy associated with Tuberous Sclerosis Complex.
Who is Dawn C. Bir?
Dawn C. Bir is a seasoned biopharmaceutical executive, newly appointed to the Board of Directors at Cassava Sciences.
What role does the Board play in Cassava's strategy?
The Board provides strategic oversight and direction, particularly as the company prepares for clinical advancements in their product pipeline.
What is simufilam?
Simufilam is an investigational treatment currently being developed by Cassava Sciences for TSC-related epilepsy and other CNS disorders.
How can investors contact Cassava Sciences?
Investors can reach out to the CFO via email at ESchoen@CassavaSciences.com for inquiries.
